12:17 PM EDT, 07/30/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) and Resilience are investing $750 million to expand the contract development and manufacturing organization's production of critical medicines at its Cincinnati facility in Ohio, US. The project includes the manufacturing of the pharmaceutical giant's KwikPen injectable device, which is used to treat diabetes and obesity, according to a Thursday release. Site expansion preparations are underway, with full operations slated to start in early 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.